Have completed the final active treatment visit for an originating study eligible to
enroll participants directly into study BREEZE-AD3 OR

Meet criteria for NCT03334396 or NCT03334422.

Exclusion Criteria:

Had investigational product permanently discontinued at any time during a previous
baricitinib study.

Had temporary investigational product interruption continue at the final study visit
of a previous baricitinib study and, in the opinion of the investigator, this poses an
unacceptable risk for the participant's participation in the study.